FATE Fate Therapeutics Inc

Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today its participation in the following upcoming investor conferences:

  • Guggenheim Healthcare Talks | Oncology Day on Thursday, February 13, 2020 at 11:30 a.m. ET in New York, NY.
  • 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 3:30 p.m. ET in New York, NY.
  • Barclays Global Healthcare Conference on Thursday, March 12, 2020 at 8:30 a.m. ET in Miami, FL.
  • Oppenheimer's 30th Annual Healthcare Conference on Wednesday, March 18, 2020 at 1:00 p.m. ET in New York, NY.

A live webcast of each presentation will be available through the investor relations section of the Company's website at . Following each live webcast, an archived replay will be available on the Company's website.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company’s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit .

Contact:

Christina Tartaglia

Stern Investor Relations, Inc.

212.362.1200

EN
07/02/2020

Underlying

FATEFate Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fate Therapeutics Inc

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
FATE FATE THERAPEUTICS INC
ACET ADICET BIO INC
ARTV ARTIVA BIOTHERAPEUTICS INC
02/27/26 February 27, 2026 1 EN
 PRESS RELEASE
Free
FATE Fate Therapeuti...

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ...

Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis patients and the first idiopathic inflammatory myopathy patient treated with FT819; First systemic sclerosis patient reaching 3-month evaluation timepoint shows meaningful disease improvement using less-intensive conditioning chemotherapy FT819 Phase 1 enrollment expanded across 16 clinical sites i...

February 26, 2026 1 EN
Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CRM SALESFORCE.COM INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NFLX NETFLIX INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
ZS ZSCALER INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
ACET INC.
PLTR ADICET BIO INC
SANA PALANTIR TECHNOLOGIES
SNOW SANA BIOTECHNOLOGY
STX SNOWFLAKE INC. CLASS A
GFS SEAGATE TECHNOLOGY HLDGS PLC
MLTX GLOBALFOUNDRIES INC
TYRA MOONLAKE IMMUNOTHERAPEUTICS
EWTX TYRA BIOSCIENCES INC
ARTV EDGEWISE THERAPEUTICS INC
DBD ARTIVA BIOTHERAPEUTICS INC
BCAX DIEBOLD NIXDORF INCORPORATED
AVTX BICARA THERAPEUTICS INC.
AVALO THERAPEUTICS INC
02/09/26 February 9, 2026 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
FATE FATE THERAPEUTICS INC
ARGX ARGENX ADS
ACET ADICET BIO INC
SANA SANA BIOTECHNOLOGY
MLTX MOONLAKE IMMUNOTHERAPEUTICS
ARTV ARTIVA BIOTHERAPEUTICS INC
AVTX AVALO THERAPEUTICS INC
02/09/26 February 9, 2026 1 EN
 PRESS RELEASE
Free
FATE Fate Therapeuti...

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq ...

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 1, 2026, the Company granted to one newly-hired non-executive employee (i) non-qualified stock options to purchase a total of 120,000 shares of the Company’s common stock...

February 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch